Annie Antar, MD, PhD, discusses the association between the symptoms of long COVID and HIV status. Annie Antar, MD, PhD, Johns Hopkins Medicine, spoke about how the likelihood of long COVID symptoms ...

Elizabeth Jones, MD, FAAD, Thomas Jefferson University Hospitals, highlights the continued relevance of older, generic dermatologic therapies despite the availability of newer, targeted treatments.

Barry Byrne, MD, PhD, pediatric cardiologist, director, Powell Gene Therapy Center, joined the University of Florida in 1997. Having taken on educational, clinical, and research roles alike, he is ...

Adeno-associated virus (AAV)–mediated gene therapy was one of the focal points of this year's Muscular Dystrophy Association conference. Here, Barry Byrne, MD, PhD, University of Florida, speaks to ...

The Conference on Retroviruses and Opportunistic Infections 2025 (CROI) featured multiple sessions that focused on breaking research and treatments.

Multiparametric quantitative MRI could potentially help differentiate between Duchenne muscular dystrophy and Becker muscular dystrophy early and improve the management of these conditions.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Toon Van Gorp, MD, PhD, is a professor of gynecologic oncology at the University of Leuven. The final analysis showed similar overall survival, progression-free survival, and objective response rates, ...

Giulio Cossu, MD, speaks to the lingering safety concerns related to ex vivo gene therapy in Duchenne muscular dystrophy (DMD) as long-term data are yet to be established.

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.

The final analysis showed similar overall survival, progression-free survival, and objective response rates, with no new safety signals identified compared with the primary analysis.

Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded ...